Logo image of INCR

INTERCURE LTD (INCR) Stock Fundamental Analysis

NASDAQ:INCR - Nasdaq - IL0011063760 - Common Stock - Currency: USD

1.44  +0.01 (+0.7%)

Fundamental Rating

3

Overall INCR gets a fundamental rating of 3 out of 10. We evaluated INCR against 194 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of INCR have multiple concerns. INCR is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

INCR had negative earnings in the past year.
In the past year INCR has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: INCR reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: INCR reported negative operating cash flow in multiple years.
INCR Yearly Net Income VS EBIT VS OCF VS FCFINCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M -60M

1.2 Ratios

INCR's Return On Assets of -8.62% is fine compared to the rest of the industry. INCR outperforms 71.13% of its industry peers.
The Return On Equity of INCR (-14.90%) is better than 74.23% of its industry peers.
Industry RankSector Rank
ROA -8.62%
ROE -14.9%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INCR Yearly ROA, ROE, ROICINCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

INCR's Gross Margin of 14.90% is in line compared to the rest of the industry. INCR outperforms 50.52% of its industry peers.
In the last couple of years the Gross Margin of INCR has declined.
The Profit Margin and Operating Margin are not available for INCR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 14.9%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-30.13%
GM growth 5Y-1.98%
INCR Yearly Profit, Operating, Gross MarginsINCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

More info and screens

2

2. Health

2.1 Basic Checks

INCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
INCR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
INCR Yearly Shares OutstandingINCR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M
INCR Yearly Total Debt VS Total AssetsINCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M 800M

2.2 Solvency

INCR has an Altman-Z score of 0.53. This is a bad value and indicates that INCR is not financially healthy and even has some risk of bankruptcy.
INCR's Altman-Z score of 0.53 is in line compared to the rest of the industry. INCR outperforms 55.15% of its industry peers.
INCR has a Debt/Equity ratio of 0.23. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.23, INCR is in line with its industry, outperforming 42.78% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Altman-Z 0.53
ROIC/WACCN/A
WACC13.02%
INCR Yearly LT Debt VS Equity VS FCFINCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M 500M

2.3 Liquidity

A Current Ratio of 1.85 indicates that INCR should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.85, INCR is doing worse than 62.89% of the companies in the same industry.
INCR has a Quick Ratio of 1.39. This is a normal value and indicates that INCR is financially healthy and should not expect problems in meeting its short term obligations.
INCR has a worse Quick ratio (1.39) than 64.95% of its industry peers.
Industry RankSector Rank
Current Ratio 1.85
Quick Ratio 1.39
INCR Yearly Current Assets VS Current LiabilitesINCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

INCR shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.71%.
INCR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -32.82%.
The Revenue has been growing by 92.97% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-8.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-822.04%
Revenue 1Y (TTM)-32.82%
Revenue growth 3Y2.83%
Revenue growth 5Y92.97%
Sales Q2Q%236.68%

3.2 Future

INCR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 561.44% yearly.
INCR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 40.52% yearly.
EPS Next Y1550%
EPS Next 2Y561.44%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year39.3%
Revenue Next 2Y40.52%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
INCR Yearly Revenue VS EstimatesINCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 100M 200M 300M 400M 500M
INCR Yearly EPS VS EstimatesINCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 0 0.5 1 1.5

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

INCR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 8.24, which indicates a very decent valuation of INCR.
INCR's Price/Forward Earnings ratio is rather cheap when compared to the industry. INCR is cheaper than 86.60% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of INCR to the average of the S&P500 Index (36.21), we can say INCR is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 8.24
INCR Price Earnings VS Forward Price EarningsINCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INCR Per share dataINCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

INCR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
INCR's earnings are expected to grow with 561.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y561.44%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INCR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INTERCURE LTD

NASDAQ:INCR (8/1/2025, 8:00:02 PM)

1.44

+0.01 (+0.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-19 2025-05-19
Earnings (Next)08-28 2025-08-28
Inst Owners5.35%
Inst Owner Change0.79%
Ins Owners30.2%
Ins Owner Change0%
Market Cap78.49M
Analysts82.86
Price TargetN/A
Short Float %0.05%
Short Ratio0.94
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 8.24
P/S 1.11
P/FCF N/A
P/OCF N/A
P/B 0.58
P/tB 1.14
EV/EBITDA N/A
EPS(TTM)-0.44
EYN/A
EPS(NY)0.17
Fwd EY12.13%
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.36
OCFYN/A
SpS1.29
BVpS2.47
TBVpS1.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.62%
ROE -14.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 14.9%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-30.13%
GM growth 5Y-1.98%
F-Score2
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.4%
Cap/Sales 2.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.85
Quick Ratio 1.39
Altman-Z 0.53
F-Score2
WACC13.02%
ROIC/WACCN/A
Cap/Depr(3y)73.35%
Cap/Depr(5y)210.09%
Cap/Sales(3y)2.61%
Cap/Sales(5y)9.25%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-822.04%
EPS Next Y1550%
EPS Next 2Y561.44%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-32.82%
Revenue growth 3Y2.83%
Revenue growth 5Y92.97%
Sales Q2Q%236.68%
Revenue Next Year39.3%
Revenue Next 2Y40.52%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-255.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year271.63%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-27.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.79%
OCF growth 3YN/A
OCF growth 5YN/A